First-trimester use of paroxetine and congenital heart defects: A population-based case-control study

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 88, Issue 2, 2010, Pages 94-100

  Bakker, Marian K ^a   Kerstjens Frederikse, Wilhelmina S ^a   Buys, Charles H C M ^a   De Walle, Hermien E K ^a   De Jong van Den Berg, Lolkje T W ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Atrium septum defects; Case control study; Congenital heart defects; Paroxetine; Selective serotonin reuptake inhibitors

Indexed keywords

PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; AUTOPSY; CASE CONTROL STUDY; CHILD; CONFIDENCE INTERVAL; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DATA ANALYSIS; DRUG USE; FEMALE; FETUS; FIRST TRIMESTER PREGNANCY; GENETIC DISORDER; HEART ATRIUM SEPTUM DEFECT; HUMAN; MAJOR CLINICAL STUDY; NETHERLANDS; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL;

ADULT; ALCOHOL DRINKING; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CASE-CONTROL STUDIES; CHILD; FEMALE; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; INFANT, NEWBORN; MATERNAL AGE; NETHERLANDS; PAROXETINE; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PRENATAL EXPOSURE DELAYED EFFECTS; SEROTONIN UPTAKE INHIBITORS; SMOKING; VITAL STATISTICS; YOUNG ADULT;

EID: 76749148062     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20641     Document Type: Article

References (20)

1. Alwan S, Reefhuis J, Rasmussen S, et al. 2007. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 356:2684-2692.
2. Bakker M, De Walle H, Dequito A, et al. 2007. Selection of controls in case-control studies on maternal medication use and risk of birth defects. Birth Defects Res A Clin Mol Teratol 79:652-656.
3. Bakker M, Kolling P, Van den Berg P, et al. 2008. Increase in use of selective serotonin reuptake inhibitors in pregnancy during the last decade, a population-based cohort study from the Netherlands Br J Clin Pharmacol 65:600-606.
4. Berard A, Ramos E, Rey E, et al. 2007. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 80:18-27.
5. Cleves M, Hobbs C, Cleves P, et al. 2007. Congenital defects among liveborn infants with Down syndrome. Birth Defects Res A Clin Mol Teratol 79:657-663.
6. Cole J, Ephross S, Cosmatos I, Walker A. 2007. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 16:1075-1085.
7. Diav-Citrin O, Shechtman S, Weinbaum D, et al. 2008. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 66:695-705.
8. GlaxoSmithKline Clinical Trial Register. 2005. Preliminary report on bupropion in pregnancy and the occurrence of cardiovascular and major congenital malformation. Available at http://ctr.gsk.co.uk/Summary/paroxetine/epip083.pdf. Accessed at November 15, 2005.
9. Hiemke C, Hartter S. 2000. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 85:11-28.
10. Hoffman J, Kaplan S. 2002. The incidence of congenital heart disease. J Am Coll Cardiol 39:1890-1900.
11. Kallen B, Otterblad O. 2007. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 79:301-308.
12. Louik C, Lin A, Werler M, et al. 2007. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356:2675-2683.
13. Merlob P, Birk E, Sirota L, et al. 2009. Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur. Birth Defects Res A Clin Mol Teratol 85:837-841.
14. Nebigil C, Maroteaux L. 2001. A novel role for serotonin in heart. Trends Cardiovasc Med 11:329-335.
15. O'Brien L, Einarson T, Sarkar M, et al. 2008. Does paroxetine cause cardiac malformations? J Obstet Gynaecol Can 30:696-701.
16. Oberlander T, Warburton W, Misri S, et al. 2008. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 83:68-76.
17. Pedersen L, Henriksen T, Vestergaard M, et al. 2009. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 339:b3569.
18. Pierpont M, Basson C, Benson D, et al. 2007. Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 115:3015-3038.
19. Reller M, Strickland M, Riehle-Colarusso T, et al. 2008. Prevalence of congenital heart defects in metropolitan Atlanta, 1998-2005. J Pediatr 153:807-813.
20. Wurst K, Poole C, Ephross S, Olshan A. 2009. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: A meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol. Sep 8, Epub ahead of print.